In the context of cancer, PD-L1 is often overexpressed on the surface of tumor cells and tumor-infiltrating immune cells. This overexpression allows the tumor to evade the immune system by inactivating T-cells that would otherwise target and destroy the cancer cells. The interaction between PD-L1 and PD-1 results in the suppression of the immune response, facilitating tumor growth and progression.
